Evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure
Dr. Waylon Weber, Ph.D. Research Scientist at Lovelace biomedical, will explain how his company uses emka TECHNOLOGIES’s rodentPACK along with IOX2 and ecgAUTO software, to perform the evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure.
Platform Session Title: Chemical and Biological Weapons
Session Time: Tuesday March 14, 2017 – 9:30 AM – 12:15 PM
Presentation Time: 3/14/2017 9:50:00 AM
Abstract Title: Evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure
Abstract Number: 1625
Where? Baltimore Convention Center – Room 314
1 W Pratt St. Baltimore MD 21201
